Brief: Pasithea Therapeutics Announces Results Of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy In Relapsing-Remitting Model Of Multiple Sclerosis
11/08/2022 15:20
Aug 11 (Reuters) - Pasithea Therapeutics Corp KTTA.O :
* PASITHEA THERAPEUTICS ANNOUNCES RESULTS OF PRECLINICAL
STUDY
DEMONSTRATING TOLERIZING VACCINE EFFICACY IN RELAPSING-REMITTING
MODEL OF MULTIPLE SCLEROSIS
Source text for Eikon: ID:nGNX5r9p1h
Further company coverage: KTTA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement